Jakafi FDA Approval History
FDA Approved: Yes (First approved November 16, 2011)
Brand name: Jakafi
Generic name: ruxolitinib
Dosage form: Tablets
Company: Incyte Corporation
Treatment for: Myelofibrosis, Polycythemia Vera, Graft-versus-host disease
Jakafi (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of:
- intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.
- polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.
- steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.
Development Timeline for Jakafi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.